An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanomaPhilippe Saïag, Caroline Dutriaux, Caroline Robert et al.|Annals of Oncology|2018Cited by 1
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasisCaroline Dutriaux, Philippe Saïag, Caroline Robert et al.|Annals of Oncology|2019Cited by 1
Issue InformationTorello Lo, Davinder Parsad, Fata Salvatores et al.|Dermatologic Therapy|2020Cited by 0